Drugs for treating advanced HCC are broadly classified into molecular-targeted drugs centred around VEGF inhibitors and ICIs, and the development of treatments has mainly focused on combinations of two or three of these drug types. Here, VEGFA is linked to hepatocellular carcinoma.